Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy

Francesca Reggiani, Giulia Gobbi, Alessia Ciarrocchi, Davide Carlo Ambrosetti, Valentina Sancisi

Research output: Contribution to journalReview articlepeer-review

Abstract

Understanding the molecular mechanisms driving resistance to anti-cancer drugs is both a crucial step to define markers of response to therapy and a clinical need in many cancer settings. YAP and TAZ transcriptional cofactors behave as oncogenes in different cancer types. Deregulation of YAP/TAZ expression or alterations in components of the multiple signaling pathways converging on these factors are important mechanisms of resistance to chemotherapy, target therapy and hormone therapy. Moreover, response to immunotherapy may also be affected by YAP/TAZ activities in both tumor and microenvironment cells. For these reasons, various compounds inhibiting YAP/TAZ function by different direct and indirect mechanisms have been proposed as a mean to counter-act drug resistance in cancer. A particularly promising approach may be to simultaneously target both YAP/TAZ expression and their transcriptional activity through BET inhibitors.

Original languageEnglish
Article number188341
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Volume1873
Issue number1
DOIs
Publication statusPublished - Jan 2020

Keywords

  • Cancer therapy
  • Drug resistance
  • Hippo
  • TAZ
  • YAP

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Fingerprint Dive into the research topics of 'Multiple roles and context-specific mechanisms underlying YAP and TAZ-mediated resistance to anti-cancer therapy'. Together they form a unique fingerprint.

Cite this